Get the Stockscreener App
11.78
0.43%
0.05
After Hours:
11.55
-0.23
-1.95%
Elicio Therapeutics Inc stock is traded at $11.78, with a volume of 75,616.
It is up +0.43% in the last 24 hours and down -3.44% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
See More
Previous Close:
$11.73
Open:
$11.98
24h Volume:
75,616
Relative Volume:
0.58
Market Cap:
$216.71M
Revenue:
-
Net Income/Loss:
$-39.57M
P/E Ratio:
-4.6003
EPS:
-2.5607
Net Cash Flow:
$-36.97M
1W Performance:
+16.29%
1M Performance:
-3.44%
6M Performance:
+11.13%
1Y Performance:
+136.55%
1-Day Range:
$11.41
$12.23
1-Week Range:
$10.00
$12.23
52-Week Range:
$4.695
$14.93
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
11.78 | 215.79M | 0 | -39.57M | -36.97M | -2.5607 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Rodman & Renshaw | Buy |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Dip Buying: How do insiders feel about Elicio Therapeutics IncTrade Risk Assessment & Weekly Setup with High ROI Potential - baoquankhu1.vn
Aug Big Picture: Does Elicio Therapeutics Inc meet Warren Buffetts criteriaExit Point & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Aug Technicals: Does Elicio Therapeutics Inc meet Warren Buffetts criteriaQuarterly Market Review & Comprehensive Market Scan Insights - baoquankhu1.vn
ELTX PE Ratio & Valuation, Is ELTX Overvalued - Intellectia AI
Discipline and Rules-Based Execution in ELTX Response - Stock Traders Daily
Elicio Therapeutics Inc (9HA.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Fund Flows: Is Elicio Therapeutics Inc a momentum stock2026 Patterns & Reliable Price Action Trade Plans - baoquankhu1.vn
Can Elicio Therapeutics Inc lead its sector in growthMarket Volume Summary & Stock Timing and Entry Methods - baoquankhu1.vn
ELTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Elicio Therapeutics (ELTX) price target increased by 12.90% to 17.85 - MSN
ELTX Stock Quote - richtv.io
Behavioral Patterns of ELTX and Institutional Flows - Stock Traders Daily
Earnings Report: Does Elicio Therapeutics Inc offer margin of safetyQuarterly Risk Review & Weekly High Return Forecasts - baoquankhu1.vn
If You Invested $1,000 in Elicio Therapeutics, Inc. (ELTX) - Stock Titan
How do insiders feel about Elicio Therapeutics IncWeekly Trend Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Macro: How do insiders feel about Elicio Therapeutics IncWeekly Trend Recap & Daily Profit Focused Screening - baoquankhu1.vn
Surprises Report: What are the future prospects of Elicio Therapeutics Inc2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Elicio Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 9HA | US28657F1030 - marketscreener.com
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know - Yahoo Finance
Valuation Update: Can Elicio Therapeutics Inc benefit from deglobalization2026 Stock Rankings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Launches New $100 Million ATM Program - The Globe and Mail
Elicio Therapeutics Reports Inducement Grants - Elicio Therapeutics
Biotech new hire lands 1,600 stock options at Elicio Therapeutics - Stock Titan
Elicio Therapeutics, Inc. Enters At Market Issuance Sales Agreement for Up to $400 Million with Nasdaq Listing - Minichart
Rodman & Renshaw initiates coverage of Elicio Therapeutics (ELTX) with buy recommendation - MSN
[EFFECT] Elicio Therapeutics, Inc. SEC Filing - Stock Titan
Elicio Therapeutics launches new $100 million at-the-market stock offering - Investing.com India
Elicio Therapeutics Launches $100M At-The-Mar... - Benzinga
Elicio Therapeutics Launches $100 Million ATM Program With B. Riley, JonesTrading and Ladenburg - TradingView
Elicio Therapeutics (NASDAQ: ELTX) launches $100M ATM, ends prior deal - Stock Titan
Elicio Therapeutics (NASDAQ: ELTX) launches $100M ATM sales program - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN) - The Globe and Mail
(ELTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
H.C. Wainwright raises Elicio Therapeutics price target to $17 By Investing.com - ca.investing.com
H.C. Wainwright raises Elicio Therapeutics price target to $17 - Investing.com
Elicio Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - The Manila Times
Elicio Therapeutics reports Q4 loss of $7.7 million - National Today
Elicio Therapeutics: Fourth Quarter Financial Overview - Bitget
Elicio Therapeutics (NASDAQ: ELTX) highlights KRAS cancer vaccine and AMP platform - Stock Titan
Elicio Therapeutics 10-K: Net loss $(39.6)M, EPS $(2.58) — Y/E Dec 31, 2025 - TradingView
Elicio Therapeutics (NASDAQ: ELTX) files $400M shelf for stock, debt and warrants - Stock Titan
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Elicio Therapeutics (Nasdaq: ELTX) narrows 2025 loss and advances ELI-002 toward Phase 3 - Stock Titan
CEO Change: Does Elicio Therapeutics Inc meet Warren Buffetts criteria2026 Big Picture & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Elicio Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating - Investing.com Nigeria
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):